The shareholders of BioInvent International AB (publ), reg no 556537-7263, are hereby invited to attend the Annual General Meeting (the "AGM") to be held at 4 p.m., Tuesday April 20, 2010 at Ideon, Sölvegatan 41 in Lund, Sweden.

 A.	NOTICE OF ATTENDANCE 

Shareholders who wish to attend the AGM must:

 (i) 	be recorded in the printout of the share register maintained by Euroclear Sweden AB ("Euroclear"), as of Wednesday April 14, 2010;

and

 (ii) 	notify the company of their intention to attend the meeting at the address Sölvegatan 41, SE-223 70 Lund, Sweden, att: Marie Serwe, by telefax 
 +46 46 211 08 06 or by telephone +46 46 286 85 50, or by e-mail  [email protected], at 4 p.m., Wednesday April 14, 2010 at the latest.

In order to participate in the proceedings at the AGM, shareholders with nominee-registered shares must request their bank or broker to have the shares temporarily owner-registered with Euroclear. Such registration must be made as per Wednesday April 14, 2010 and the bank or broker should therefore be notified in due time before said date.

On giving notice of attendance, the shareholder shall state name, personal identity number/registration number, number of shares held, phone number and, if applicable, the name of the representative. Proxy to act on behalf of a shareholder should be sent together with the notice of attendance. Representative of a legal person shall hand in a copy of a registration certificate or similar papers of authorisation. The company will supply proxy forms upon request from a shareholder.

 B. 	AGENDA FOR THE MEETING

Proposal for Agenda

1. Opening of the Meeting.
2. Election of Chairman of the Meeting.
3. Preparation and approval of the voting list.
4. Election of persons to check the minutes.
5. Determination of compliance with the rules of convocation.
6. Approval of the Agenda.
7. The Managing Director's report for the financial year 2009.
8. Account for the Board's and the committees' work for the financial year 2009.
9. Presentation of (a) the Annual Report and the Auditor's Report and the Consolidated Financial Statements and the Group Auditor's Report for the financial year 2009 and (b) the statement by the Auditor on the compliance with the guidelines for remuneration to management applicable since the last AGM.
10. Resolutions regarding
(a) adoption of the Statement of Income and the Balance Sheet and the Consolidated Statement of Income and the Consolidated Balance Sheet,
(b) appropriation of the company's result according to the adopted Balance Sheet, and
© discharge from liability of the Board of Directors and the Managing Director.
11. Establishment of the number of members and deputy members of the Board of Directors.
12. Establishment of fees for the board members.
13. Election of board members and Chairman of the Board of Directors.
14. Determination of guidelines for remuneration to management.
15. Closing of the Meeting.

Proposals regarding items on the Agenda

Election of Chairman of the Meeting (item 2)

The Nomination Committee has proposed that the Chairman of the Board of Directors, Karl Olof Borg, shall be Chairman of the Meeting.

Appropriation of the company's result (item 10 b)

The Board of Directors proposes that the statutory reserve be reduced by SEK
-175,453,767 to cover the accumulated loss.

Elections (items 11-13)

The Nomination Committee, consisting of Lennart Hansson (Stiftelsen Industrifonden), Ulrica Slåne (Tredje AP-fonden), Karin Lind-Mörnesten (Östersjöstiftelsen) and Karl Olof Borg (Chairman of the Board of Directors), has informed the company of the following proposals.

The number of board members shall be eight, without deputy members.

It is proposed to re-elect the ordinary board members Karl Olof Borg, Carl Borrebaeck, Lars Ingelmark, Elisabeth Lindner, Svein Mathisen, Björn Nilsson and Kenth Petersson. In addition, it is proposed that Lars Backsell shall be newly elected. Lars Henriksson has declined re-election. Karl Olof Borg is proposed to remain as Chairman of the Board of Directors.

Lars Backsell, born 1952, Master of Business Administration, Stockholm School of Economics, and graduate from the AMP at INSEAD, Fontainebleu. Chairman of Recipharm AB since 2007. Held his latest operative position as CEO of Recip AB 1994-2007. Lars Backsell is also a member of the Board of Lund University Bioscience AB (LuBio) and a member of IVA - the Royal Swedish Academy of Engineering Sciences.

Fees to the board members shall be paid in the amounts of SEK 400,000 to the Chairman of the Board and SEK 160,000 to each of the other board members, who are not employed by the company. In addition hereto, fees are proposed for committee work (however not to the Chairman of the Board) in the amounts of SEK 20,000 to each of the members in the Remuneration Committee, of SEK 50,000 to the Chairman of the Audit Committee and of SEK 40,000 to each of the other members in the Audit Committee.

Resolution regarding the determination of guidelines for remuneration to management (item 14)

The Board of Directors' complete proposal for guidelines for remuneration to management appear from the Directors' Report and is unchanged in relation to the guidelines that were resolved last year. The proposal principally entails that the remuneration and employment terms for the management shall be in accordance with market conditions. In addition to the fixed yearly salary, the management may obtain variable remuneration, which shall be limited and mainly related to technical and commercial milestones within the own pharmaceutical projects. Remuneration may also emanate from warrants or other share related incentive programs resolved by the general meeting.

 C.	DOCUMENTATION

The Accounts and the Consolidated Accounts and the Auditor's statement under item 9 (b) will as from Tuesday April 6, 2010 be available at the company's premises in Lund and upon request be sent to shareholders who request it and state their address. The documents will also be available at the website of the company, www.bioinvent.se.

The total number of shares and votes in the company amounts to 61,095,689.

___

Lund in March 2010
The Board of Directors
BIOINVENT INTERNATIONAL AB (PUBL)

-- END --

Notes to Editors:

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based
pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, OrbusNeich, UCB and XOMA. More information is available at www.bioinvent.com.

For further information, please contact:

 BioInvent International AB
 Svein Mathisen	
 President & CEO	
 Tel: +46 (0)46-286 85 67	
 Mobile: +46 (0)708-97 82 13	
 E-mail: [email protected]	

Cristina Glad
Executive Vice President
Tel: +46 (0)46-286 85 51
Mobile: +46 (0)708-16 85 70
E-mail: [email protected]

 BioInvent International AB (publ)	
 Co. reg. No. 556537-7263,		
 Address:  Sölvegatan 41		
 Mailing address: SE-223 70 LUND	
 Tel: +46 (0)46 286 85 50		
 [email protected]		
 www.bioinvent.com		

BioInvent publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on 18 March 2010 at 8.30 a.m. CET.